Mercy BioAnalytics
Mercy BioAnalytics is dedicated to saving lives through the early detection of cancer. They develop innovative, highly accurate, low-cost blood-based tests using their proprietary Mercy Halo™ platform, which leverages extracellular vesicles (EVs) for early cancer detection. Their mission is to make cancer screening broadly accessible and improve patient outcomes by detecting cancer at its earliest, most treatable stages.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Mercy Halo™ platform
A proprietary technology that uses low-cost qPCR and extracellular vesicles to identify cancer-associated biomarkers on individual EVs, enabling early detection of cancer.
Blood-based cancer screening tests
Tests developed for ovarian, lung, and other cancers that detect colocalized biomarkers on extracellular vesicles for early diagnosis.
Mercy Halo™ platform
A proprietary technology that uses low-cost qPCR and extracellular vesicles to identify cancer-associated biomarkers on individual EVs, enabling early detection of cancer.
Blood-based cancer screening tests
Tests developed for ovarian, lung, and other cancers that detect colocalized biomarkers on extracellular vesicles for early diagnosis.
Services
Early cancer detection tests
Development of highly sensitive, specific, and low-cost blood-based tests for early cancer detection using the Mercy Halo™ platform.
Clinical validation and studies
Conducting rigorous clinical studies and validation of their tests in populations to ensure effectiveness and reliability.
Partnership and collaboration
Working with pharmaceutical companies and other partners to accelerate clinical development, trial enrollment, and diagnostic support.
Early cancer detection tests
Development of highly sensitive, specific, and low-cost blood-based tests for early cancer detection using the Mercy Halo™ platform.
Clinical validation and studies
Conducting rigorous clinical studies and validation of their tests in populations to ensure effectiveness and reliability.
Partnership and collaboration
Working with pharmaceutical companies and other partners to accelerate clinical development, trial enrollment, and diagnostic support.
News & Updates
Presentation at the American Association for Cancer Research Annual Meeting in Chicago, IL, April 25-30, 2025.
Presentation at the American College of Obstetricians and Gynecologists Annual Meeting in Minneapolis, MN, May 15-18, 2025.
Presentation at the American Thoracic Society International Conference in San Francisco, CA, May 18-21, 2025.
The publications describe the foundational technology and validation of the Mercy Halo™ ovarian cancer screening test.
Recognition for innovative extracellular vesicle-based liquid biopsy technology for early cancer detection.
Mercy BioAnalytics received FDA Breakthrough Device designation for their ovarian cancer screening test.
Presentation at the American Association for Cancer Research Annual Meeting in Chicago, IL, April 25-30, 2025.
Presentation at the American College of Obstetricians and Gynecologists Annual Meeting in Minneapolis, MN, May 15-18, 2025.
Presentation at the American Thoracic Society International Conference in San Francisco, CA, May 18-21, 2025.
The publications describe the foundational technology and validation of the Mercy Halo™ ovarian cancer screening test.
Recognition for innovative extracellular vesicle-based liquid biopsy technology for early cancer detection.
Mercy BioAnalytics received FDA Breakthrough Device designation for their ovarian cancer screening test.